Purple Biotech Ltd. Overview
Pro stress-test →Purple Biotech is a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The company is focused on advancing its lead program, CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells.
Strategic Profile
Pro stress-test →Capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers. The platform consists of capped tri-specific antibodies with IM1240 as the lead 5T4-targeting candidate and IM1305 as the TROP2-targeting development candidate.
Competitive Landscape
Pro stress-test →Purple Biotech's CAPTN-3 platform of masked tri-specific antibodies targets tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment. This positions the company in the competitive oncology immunotherapy space against both established therapeutics and other next-generation T-cell engager developers.
Industry Context
Purple Biotech Ltd. operates in Oncology immunotherapy.
Key facts
Founded: N/A · Headquarters: Rehovot, Israel · Employees: N/A · Revenue: N/A · Market cap: N/A